Immunological processes play a role in most cell interactions and diseases across all systems. They are a critical factor in the development of new therapies. Empower your earliest decisions and mitigate risk with actionable immunology data from Charles River. From proving mechanism of action (MoA) and efficacy to using clinically relevant biomarkers to establish target engagement and predict adverse immune reactions, our team of 200+ in-house immunologists and therapeutic area experts can accelerate the identification and development of the best version of your drug.
90% of medicines that reach the clinic never make it to the market because of safety or efficacy. Failing earlier in the process greatly reduces cycle times and costs.
The average cost of progressing a drug from invention to market is $2.6B. This includes the price of late-stage failures that could have been avoided with more complete data, and investment in operations that do not provide a reliable return.
Building evidence for mechanism of action (MoA) early into the discovery stage, eliminating compounds that have mechanism-based toxicity, and selecting relevant translational models can significantly reduce attrition.
Save time and money by choosing Charles River as partner for your entire program. With science and project knowledge shared across teams and phases, you can monitor the same target engagement biomarkers from early discovery to the clinic.
Primary cell assays can provide early information on efficacy, mechanism of action (MoA) and target engagement. In vitro studies reduce costs by shifting attrition to early phases, demonstrating the ability to translate into the clinic and de-risking the progression into expensive in vivo models.
Learn MoreThe increase in biologics and immune therapies, and their inherent risk in triggering adverse immune responses, increases our need to mitigate risk. Mapping this immune response ex vivo in early development ensures that you progress the best version of your drug.
Learn MoreIn vivo pharmacodynamic (PD) models evaluate target engagement and function of a therapeutic before entering more disease-specific models. PD models provide valuable early information on whether your therapy is hitting its intended target and whether the function of your target cell is being modulated in a way you would predict.
Learn MoreSelecting the appropriate animal model is central in reducing attrition rates; Charles River routinely run in vivo efficacy models that closely mimic human disease and the interaction of the immune system e.g. Rheumatoid arthritis models, SLE studies, and infection models which model host-pathogen interactions.
Learn MoreThe expanding Immunology portfolio with scientific depth and expertise can provide in vitro, ex vivo and in vivo testing support for drug development programs from IND-enabling programs to the clinic.
Learn MoreOur clinical sample analysis services allow us to map immune function into the clinic to confirm the drug is interacting with its target all the way through the drug discovery process.
Learn MorePrimary cell assays can provide early information on efficacy, mechanism of action (MoA) and target engagement. In vitro studies reduce costs by shifting attrition to early phases, demonstrating the ability to translate into the clinic and de-risking the progression into expensive in vivo models.
Learn MoreThe increase in biologics and immune therapies, and their inherent risk in triggering adverse immune responses, increases our need to mitigate risk. Mapping this immune response ex vivo in early development ensures that you progress the best version of your drug.
Learn MoreIn vivo pharmacodynamic (PD) models evaluate target engagement and function of a therapeutic before entering more disease-specific models. PD models provide valuable early information on whether your therapy is hitting its intended target and whether the function of your target cell is being modulated in a way you would predict.
Learn MoreSelecting the appropriate animal model is central in reducing attrition rates; Charles River routinely run in vivo efficacy models that closely mimic human disease and the interaction of the immune system e.g. Rheumatoid arthritis models, SLE studies, and infection models which model host-pathogen interactions.
Learn MoreThe expanding Immunology portfolio with scientific depth and expertise can provide in vitro, ex vivo and in vivo testing support for drug development programs from IND-enabling programs to the clinic.
Learn MoreOur clinical sample analysis services allow us to map immune function into the clinic to confirm the drug is interacting with its target all the way through the drug discovery process.
Learn MorePrimary cell assays can provide early information on efficacy, mechanism of action (MoA) and target engagement. In vitro studies reduce costs by shifting attrition to early phases, demonstrating the ability to translate into the clinic and de-risking the progression into expensive in vivo models.
Learn MoreThe increase in biologics and immune therapies, and their inherent risk in triggering adverse immune responses, increases our need to mitigate risk. Mapping this immune response ex vivo in early development ensures that you progress the best version of your drug.
Learn MoreIn vivo pharmacodynamic (PD) models evaluate target engagement and function of a therapeutic before entering more disease-specific models. PD models provide valuable early information on whether your therapy is hitting its intended target and whether the function of your target cell is being modulated in a way you would predict.
Learn MoreSelecting the appropriate animal model is central in reducing attrition rates; Charles River routinely run in vivo efficacy models that closely mimic human disease and the interaction of the immune system e.g. Rheumatoid arthritis models, SLE studies, and infection models which model host-pathogen interactions.
Learn MoreThe expanding Immunology portfolio with scientific depth and expertise can provide in vitro, ex vivo and in vivo testing support for drug development programs from IND-enabling programs to the clinic.
Learn MoreOur clinical sample analysis services allow us to map immune function into the clinic to confirm the drug is interacting with its target all the way through the drug discovery process.
Learn MorePrimary cell assays can provide early information on efficacy, mechanism of action (MoA) and target engagement. In vitro studies reduce costs by shifting attrition to early phases, demonstrating the ability to translate into the clinic and de-risking the progression into expensive in vivo models.
Learn MoreThe increase in biologics and immune therapies, and their inherent risk in triggering adverse immune responses, increases our need to mitigate risk. Mapping this immune response ex vivo in early development ensures that you progress the best version of your drug.
Learn MoreIn vivo pharmacodynamic (PD) models evaluate target engagement and function of a therapeutic before entering more disease-specific models. PD models provide valuable early information on whether your therapy is hitting its intended target and whether the function of your target cell is being modulated in a way you would predict.
Learn MoreSelecting the appropriate animal model is central in reducing attrition rates; Charles River routinely run in vivo efficacy models that closely mimic human disease and the interaction of the immune system e.g. Rheumatoid arthritis models, SLE studies, and infection models which model host-pathogen interactions.
Learn MoreThe expanding Immunology portfolio with scientific depth and expertise can provide in vitro, ex vivo and in vivo testing support for drug development programs from IND-enabling programs to the clinic.
Learn MoreOur clinical sample analysis services allow us to map immune function into the clinic to confirm the drug is interacting with its target all the way through the drug discovery process.
Learn MorePrimary cell assays can provide early information on efficacy, mechanism of action (MoA) and target engagement. In vitro studies reduce costs by shifting attrition to early phases, demonstrating the ability to translate into the clinic and de-risking the progression into expensive in vivo models.
Learn MoreThe increase in biologics and immune therapies, and their inherent risk in triggering adverse immune responses, increases our need to mitigate risk. Mapping this immune response ex vivo in early development ensures that you progress the best version of your drug.
Learn MoreIn vivo pharmacodynamic (PD) models evaluate target engagement and function of a therapeutic before entering more disease-specific models. PD models provide valuable early information on whether your therapy is hitting its intended target and whether the function of your target cell is being modulated in a way you would predict.
Learn MoreSelecting the appropriate animal model is central in reducing attrition rates; Charles River routinely run in vivo efficacy models that closely mimic human disease and the interaction of the immune system e.g. Rheumatoid arthritis models, SLE studies, and infection models which model host-pathogen interactions.
Learn MoreThe expanding Immunology portfolio with scientific depth and expertise can provide in vitro, ex vivo and in vivo testing support for drug development programs from IND-enabling programs to the clinic.
Learn MoreOur clinical sample analysis services allow us to map immune function into the clinic to confirm the drug is interacting with its target all the way through the drug discovery process.
Learn MorePrimary cell assays can provide early information on efficacy, mechanism of action (MoA) and target engagement. In vitro studies reduce costs by shifting attrition to early phases, demonstrating the ability to translate into the clinic and de-risking the progression into expensive in vivo models.
Learn MoreThe increase in biologics and immune therapies, and their inherent risk in triggering adverse immune responses, increases our need to mitigate risk. Mapping this immune response ex vivo in early development ensures that you progress the best version of your drug.
Learn MoreIn vivo pharmacodynamic (PD) models evaluate target engagement and function of a therapeutic before entering more disease-specific models. PD models provide valuable early information on whether your therapy is hitting its intended target and whether the function of your target cell is being modulated in a way you would predict.
Learn MoreSelecting the appropriate animal model is central in reducing attrition rates; Charles River routinely run in vivo efficacy models that closely mimic human disease and the interaction of the immune system e.g. Rheumatoid arthritis models, SLE studies, and infection models which model host-pathogen interactions.
Learn MoreThe expanding Immunology portfolio with scientific depth and expertise can provide in vitro, ex vivo and in vivo testing support for drug development programs from IND-enabling programs to the clinic.
Learn MoreOur clinical sample analysis services allow us to map immune function into the clinic to confirm the drug is interacting with its target all the way through the drug discovery process.
Learn MoreWe’ve gathered these immunology-related scientific webinars, videos, blogs, and articles into one convenient library to help you explore the latest advances and trends.
Immunology plays a key role in cell interactions and therefore most disease areas. Click on a tissue type to see how our immunology expertise can help drug development in that therapeutic area.
Sharing decades of immunology experience across all therapeutic areas, the Charles River team is committed to helping our clients advance life-saving therapies to market. We encourage you to meet and connect with our scientists.
Rhiannon leads and designs projects for clients in the fields of autoimmunity, inflammation and oncology. She has completed a Wellcome Trust Career Re-entry Fellowship, focusing on the role of T cells in epithelial repair in the gut and skin, a six-year fellowship at the NIH, NCI where her research focused on T cell development and tumour immunology, a postdoctoral position at the University of Bristol, studying T cell responses to tumours and PhD studying a gene which drives breast cancer metastasis.
Find her on LinkedIn
Christina received her PhD in cellular and molecular pharmacology and physiology from the University of Nevada, Reno, School of Medicine. Over the course of her career, she has worked on an extensive breadth and number of compounds in the areas of pathology, toxicology (with an emphasis on immunotoxicology studies), analytical chemistry and immunobiology. Prior to taking on her role as Senior Director of Global Laboratory Sciences and head of our Immunology Center of Excellence, she led the laboratory sciences group in Nevada overseeing interactions with regulatory authorities and Sponsors, interpretation and reporting of study data, and the conduct, management and regulatory compliance of assigned nonclinical and clinical studies.
Find her on LinkedIn
Rana received both an MSc and PhD in pharmacology from the Université de Sherbrooke. Following her postdoctoral training at McGill University, Rana joined Charles River, where she and her team focus on inflammation, immunology, autoimmune, IBD, respiratory, skin, and joint diseases. She has received several scientific awards and authored more than 105 peer-reviewed publications which have appeared in Scientific American, the Journal of Bone and Mineral Research and Bone, and others. She is a Diplomate of the American Board of Toxicology.
Find her on LinkedIn
Alan is a pharmacologist who has worked in respiratory research for over 25 years, exclusively within the pharmaceutical industry. Prior to Charles River, he was both Discovery Director for early development and Head of Respiratory Disease Sciences at AstraZeneca, where he was responsible for progressing compounds into Phase IIB clinical studies. He has delivered more than 20 candidate drugs into clinical development, authored more than 200 peer-reviewed publications, and completed Edgar Allen Fellowship from the University of Sheffield.
Find him on LinkedIn
David has a PhD in Immunology and 20+ years’ experience in academia and industry with organizations such as Lexicon Pharmaceuticals and MD Anderson Cancer Center. With expertise in immunological assays, in vivo models of autoimmunity and inflammation, tumor biology, immunotherapy, animal pharmacology studies, biomarkers, and interpretation of complex immunological data, he oversees the design, execution and reporting of client oncology studies and global research and development efforts. He has authored more than 30 peer-reviewed papers.
Find him on LinkedIn
With numerous roles in drug development leadership over the course his career, John currently oversees all aspects of partnered integrated drug discovery projects at Charles River. Working with a talented team of subject matter experts, he ensures a project’s scientific progression from early business development discussions through to established relationships that deliver quality clinical candidates. He is a member of the Royal Society of Chemistry, and his research has appeared in more than 150 peer-reviewed papers and patents.
Find him on LinkedInContact us at 877.CRIVER.1 for general inquiries or use the form to find the direct phone number or contact email for your specific needs.
